Literature DB >> 8900234

Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease.

E Hahnen1, J Schönling, S Rudnik-Schöneborn, K Zerres, B Wirth.   

Abstract

Spinal muscular atrophy (SMA) is a frequent autosomal recessive neurodegenerative disorder leading to weakness and atrophy of voluntary muscles. The survival motor-neuron gene (SMN), a strong candidate for SMA, is present in two highly homologous copies (telSMN and cenSMN) within the SMA region. Only five nucleotide differences within the region between intron 6 and exon 8 distinguish these homologues. Independent of the severity of the disease, 90%-98% of all SMA patients carry homozygous deletions in telSMN, affecting either exon 7 or both exons 7 and 8. We present the molecular analysis of 42 SMA patients who carry homozygous deletions of telSMN exon 7 but not of exon 8. The question arises whether in these cases the telSMN is truncated upstream of exon 8 or whether hybrid SMN genes exist that are composed of centromeric and telomeric sequences. By a simple PCR-based assay we demonstrate that in each case the remaining telSMN exon 8 is part of a hybrid SMN gene. Sequencing of cloned hybrid SMN genes from seven patients, as well as direct sequencing and single-strand conformation analysis of all patients, revealed the same composition in all but two patients: the base-pair differences in introns 6 and 7 and exon 7 are of centromeric origin whereas exon 8 is of telomeric origin. Nonetheless, haplotype analysis with polymorphic multicopy markers, Ag1-CA and C212, localized at the 5' end of the SMN genes suggests different mechanisms of occurrence, unequal rearrangements, and gene conversion involving both copies of the SMN genes. In approximately half of all patients, we identified a consensus haplotype, suggesting a common origin. Interestingly, we identified a putative recombination hot spot represented by recombination-stimulating elements (TGGGG and TGAGGT) in exon 8 that is homologous to the human deletion-hot spot consensus sequence in the immunoglobulin switch region, the alpha-globin cluster, and the polymerase alpha arrest sites. This may explain why independent hybrid SMN genes show identical sequences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900234      PMCID: PMC1914839     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

Review 1.  Molecular aspects of heavy-chain class switching.

Authors:  C A Gritzmacher
Journal:  Crit Rev Immunol       Date:  1989       Impact factor: 2.214

2.  A multicopy dinucleotide marker that maps close to the spinal muscular atrophy gene.

Authors:  A H Burghes; S E Ingraham; M McLean; T G Thompson; J D McPherson; Z Kote-Jarai; J D Carpten; C J DiDonato; J E Ikeda; L Surh
Journal:  Genomics       Date:  1994-05-15       Impact factor: 5.736

3.  Association between Ag1-CA alleles and severity of autosomal recessive proximal spinal muscular atrophy.

Authors:  C J DiDonato; K Morgan; J D Carpten; P Fuerst; S E Ingraham; G Prescott; J D McPherson; B Wirth; K Zerres; O Hurko
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

4.  Complex repetitive arrangements of gene sequence in the candidate region of the spinal muscular atrophy gene in 5q13.

Authors:  A M Theodosiou; K E Morrison; A M Nesbit; R J Daniels; L Campbell; M J Francis; Z Christodoulou; K E Davies
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

5.  Construction of a yeast artificial chromosome contig spanning the spinal muscular atrophy disease gene region.

Authors:  P W Kleyn; C H Wang; L L Lien; E Vitale; J Pan; B M Ross; A Grunn; D A Palmer; D Warburton; L M Brzustowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  Charcot-Marie-Tooth type 1A duplication appears to arise from recombination at repeat sequences flanking the 1.5 Mb monomer unit.

Authors:  L Pentao; C A Wise; A C Chinault; P I Patel; J R Lupski
Journal:  Nat Genet       Date:  1992-12       Impact factor: 38.330

7.  De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

Authors:  J Melki; S Lefebvre; L Burglen; P Burlet; O Clermont; P Millasseau; S Reboullet; B Bénichou; M Zeviani; D Le Paslier
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  DNA deletion associated with hereditary neuropathy with liability to pressure palsies.

Authors:  P F Chance; M K Alderson; K A Leppig; M W Lensch; N Matsunami; B Smith; P D Swanson; S J Odelberg; C M Disteche; T D Bird
Journal:  Cell       Date:  1993-01-15       Impact factor: 41.582

9.  Gene conversion in steroid 21-hydroxylase genes.

Authors:  K Urabe; A Kimura; F Harada; T Iwanaga; T Sasazuki
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

10.  Mapping of two new markers within the smallest interval harboring the spinal muscular atrophy locus by family and radiation hybrid analysis.

Authors:  C Brahe; I Velonà; G van der Steege; S Zappata; A Y van de Veen; J Osinga; C M Tops; R Fodde; P M Khan; C H Buys
Journal:  Hum Genet       Date:  1994-05       Impact factor: 4.132

View more
  22 in total

1.  Molecular study of spinal muscular atrophy patients with hybrid genes in Bulgaria.

Authors:  I Kremensky; S Jankova; E Bochukova; M Uzunova; I Litvinenko; A Jordanova
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling.

Authors:  B Wirth; T Schmidt; E Hahnen; S Rudnik-Schöneborn; M Krawczak; B Müller-Myhsok; J Schönling; K Zerres
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

3.  Maternal mosaicism for a second mutational event in a type I spinal muscular atrophy family.

Authors:  L Campbell; R J Daniels; V Dubowitz; K E Davies
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 4.  When is a deletion not a deletion? When it is converted.

Authors:  A H Burghes
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

5.  Spinal muscular atrophy genetic testing experience at an academic medical center.

Authors:  Shuji Ogino; Debra G B Leonard; Hanna Rennert; Robert B Wilson
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

6.  Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR.

Authors:  Deborah L Stabley; Jennifer Holbrook; Mena Scavina; Thomas O Crawford; Kathryn J Swoboda; Katherine M Robbins; Matthew E R Butchbach
Journal:  Neurogenetics       Date:  2021-01-07       Impact factor: 2.660

7.  Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling.

Authors:  Laura Alías; Sara Bernal; Maite Calucho; Elisabeth Martínez; Francesca March; Pia Gallano; Pablo Fuentes-Prior; Anna Abuli; Clara Serra-Juhe; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

8.  Reduced levels of survival motor neuron protein leads to aberrant motoneuron growth in a Xenopus model of muscular atrophy.

Authors:  Qods Ymlahi-Ouazzani; Odile J Bronchain; Elodie Paillard; Chantal Ballagny; Albert Chesneau; Aurélie Jadaud; André Mazabraud; Nicolas Pollet
Journal:  Neurogenetics       Date:  2009-06-11       Impact factor: 2.660

Review 9.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

10.  TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy.

Authors:  Michael A Gitcho; Eileen H Bigio; Manjari Mishra; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Rosa Rademakers; Sumi Chakraverty; Carlos Cruchaga; John C Morris; Alison M Goate; Nigel J Cairns
Journal:  Acta Neuropathol       Date:  2009-07-18       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.